Fenwick Partner Robert Freedman Discusses Alternative Financing Strategies to Going Public

Fenwick partner Robert Freedman was quoted in Law360 on alternative financing options private life sciences companies are considering as the IPO market remains slow and is not expected to recover until late 2023.

A recent Fenwick IPO report noted over half of life sciences companies ranked cost-cutting as their top alternative to an IPO, while 42% find private financing an optimal alternative. Companies are also considering licensing collaborations and mergers, including reverse mergers with dormant publicly traded companies.

Commenting on the unconventional strategy of going public through a reverse merger, Freedman told Law360 "Even if a lot of them aren't closing per se, I can tell you that a lot of our private companies are pursuing the concept at least.”

Read the full article here (subscription required).